Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Aligos Therapeutics, Inc. (ALGS) had Weighted-Average Shares Outstanding (Diluted) of 9.88M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$2.19M |
|
$-24.19M |
|
-- |
|
$2.19M |
|
$90.17M |
|
$-87.98M |
|
$64.11M |
|
$-23.88M |
|
$-23.88M |
|
$-24.19M |
|
$-24.19M |
|
$-24.19M |
|
$-24.19M |
|
$-87.98M |
|
$-89.24M |
|
9.88M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
9.88M |
$-2.45 |
|
$-2.45 |
|
| Balance Sheet Financials | |
$82.86M |
|
$1.87M |
|
$5.67M |
|
$88.53M |
|
$21.23M |
|
-- |
|
$13.76M |
|
$34.99M |
|
$53.55M |
|
$53.55M |
|
$53.55M |
|
6.18M |
|
| Cash Flow Statement Financials | |
$-82.50M |
|
$-37.83M |
|
$101.64M |
|
$37.11M |
|
$18.41M |
|
$-18.69M |
|
$5.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.90 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
100.00% |
|
-4024.93% |
|
-4024.93% |
|
-4082.48% |
|
-1092.36% |
|
-1106.72% |
|
$-82.94M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-45.18% |
|
-45.18% |
|
-27.33% |
|
-45.18% |
|
$8.67 |
|
$-8.39 |
|
$-8.35 |
|